SG11201402347YA - Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of dry eye syndrome - Google Patents
Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of dry eye syndromeInfo
- Publication number
- SG11201402347YA SG11201402347YA SG11201402347YA SG11201402347YA SG11201402347YA SG 11201402347Y A SG11201402347Y A SG 11201402347YA SG 11201402347Y A SG11201402347Y A SG 11201402347YA SG 11201402347Y A SG11201402347Y A SG 11201402347YA SG 11201402347Y A SG11201402347Y A SG 11201402347YA
- Authority
- SG
- Singapore
- Prior art keywords
- cell
- treatment
- signal transduction
- dry eye
- transduction pathway
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Marine Sciences & Fisheries (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Toxicology (AREA)
- Ophthalmology & Optometry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP2011006003 | 2011-11-30 | ||
| PCT/EP2012/004952 WO2013079213A1 (en) | 2011-11-30 | 2012-11-30 | Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of dry eye syndrome |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201402347YA true SG11201402347YA (en) | 2014-06-27 |
Family
ID=47324033
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201402347YA SG11201402347YA (en) | 2011-11-30 | 2012-11-30 | Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of dry eye syndrome |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20140309400A1 (ja) |
| JP (1) | JP2015500213A (ja) |
| KR (1) | KR20140099526A (ja) |
| CN (1) | CN104023736A (ja) |
| AU (1) | AU2012344299A1 (ja) |
| BR (1) | BR112014013041A2 (ja) |
| CA (1) | CA2855223A1 (ja) |
| EA (1) | EA201491062A1 (ja) |
| IL (1) | IL232699A0 (ja) |
| MX (1) | MX2014006399A (ja) |
| SG (1) | SG11201402347YA (ja) |
| WO (1) | WO2013079213A1 (ja) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2807036C (en) | 2010-10-14 | 2018-01-16 | Xigen S.A. | Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of chronic or non-chronic inflammatory eye diseases |
| WO2013091670A1 (en) | 2011-12-21 | 2013-06-27 | Xigen S.A. | Novel jnk inhibitor molecules for treatment of various diseases |
| WO2014206426A1 (en) * | 2013-06-26 | 2014-12-31 | Xigen Inflammation Ltd. | New use for jnk inhibitor molecules for treatment of various diseases |
| ES2870085T3 (es) | 2013-06-26 | 2021-10-26 | Xigen Inflammation Ltd | Inhibidores peptídicos permeables a células de la ruta de transducción de señales de JNK para el tratamiento de la cistitis |
| WO2015197097A1 (en) | 2014-06-26 | 2015-12-30 | Xigen Inflammation Ltd. | New use for jnk inhibitor molecules for treatment of various diseases |
| WO2014206427A1 (en) | 2013-06-26 | 2014-12-31 | Xigen Inflammation Ltd. | New use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases |
| US10307456B2 (en) * | 2015-02-25 | 2019-06-04 | Mackay Memorial Hospital | Use of short synthetic peptide for the treatment and/or prophylaxis of dry eye disease |
| KR101778004B1 (ko) * | 2015-06-22 | 2017-09-15 | (주) 에빅스젠 | 이마티닙을 유효성분으로 포함하는 안구 건조 질환 예방 및 치료용 약학 조성물 |
| US20180170983A1 (en) * | 2015-06-26 | 2018-06-21 | Xigen Inflammation Ltd. | New Use of Cell-Permeable Peptide Inhibitors of the JNK Signal Transduction Pathway for the Treatment of Mild Cognitive Impairment |
| KR101690539B1 (ko) | 2015-07-30 | 2016-12-29 | 주식회사 아이바이오코리아 | 건성안 예방 또는 치료용 약학조성물 |
| WO2018029336A1 (en) | 2016-08-12 | 2018-02-15 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for determining whether a subject was administered with an activator of the ppar beta/delta pathway. |
| CN110945012A (zh) * | 2017-05-17 | 2020-03-31 | 株式会社柳柳制药 | 新型肽和用于治疗眼病的包含所述新型肽作为活性药物成分的药物组合物 |
| DK3720428T3 (da) * | 2017-12-04 | 2023-03-20 | Salvat Lab Sa | Oftalmisk topisk sammensætning omfattende dobesilsyre til behandling af sygdomme i det bageste øjensegment |
| US11613558B2 (en) | 2018-11-14 | 2023-03-28 | Yuyu Pharma, Inc. | Peptides and pharmaceutical compositions for treating eye diseases |
| KR102429281B1 (ko) | 2020-05-25 | 2022-08-05 | (주)노바셀테크놀로지 | 신규 안구건조증 치료용 약학적 조성물 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4980286A (en) | 1985-07-05 | 1990-12-25 | Whitehead Institute For Biomedical Research | In vivo introduction and expression of foreign genetic material in epithelial cells |
| EP0832980B1 (en) | 1989-01-23 | 2002-06-19 | Chiron Corporation | Recombinant therapies for infection and hyperproliferative disorders |
| GB8919607D0 (en) | 1989-08-30 | 1989-10-11 | Wellcome Found | Novel entities for cancer therapy |
| US5804604A (en) | 1989-12-21 | 1998-09-08 | Biogen, Inc. | Tat-derived transport polypeptides and fusion proteins |
| US5670617A (en) | 1989-12-21 | 1997-09-23 | Biogen Inc | Nucleic acid conjugates of tat-derived transport polypeptides |
| WO1994008598A1 (en) | 1992-10-09 | 1994-04-28 | Advanced Tissue Sciences, Inc. | Liver reserve cells |
| AU705563B2 (en) | 1995-07-28 | 1999-05-27 | Marie Curie Cancer Care | Transport proteins and their uses |
| US6610820B1 (en) * | 1999-10-12 | 2003-08-26 | University Of Lausanne | Cell-permeable peptide inhibitors of the JNK signal transduction pathway |
| US20030108539A1 (en) * | 2000-02-14 | 2003-06-12 | Christophe Bonny | Cell-permeable peptide inhibitors of the JNK signal transduction pathway |
| EP1542768A1 (en) * | 2002-09-20 | 2005-06-22 | Alcon, Inc. | Use of cytokine synthesis inhibitors for the treatment of dry eye disorders |
| US8080517B2 (en) * | 2005-09-12 | 2011-12-20 | Xigen Sa | Cell-permeable peptide inhibitors of the JNK signal transduction pathway |
| WO2007031098A1 (en) * | 2005-09-12 | 2007-03-22 | Xigen S.A. | Cell-permeable peptide inhibitors of the jnk signal transduction pathway |
| EP2285364B1 (en) * | 2008-05-07 | 2015-01-21 | The Regents of The University of California | Therapeutic replenishment and enrichment of ocular surface lubrication |
-
2012
- 2012-11-30 SG SG11201402347YA patent/SG11201402347YA/en unknown
- 2012-11-30 MX MX2014006399A patent/MX2014006399A/es unknown
- 2012-11-30 CN CN201280059139.2A patent/CN104023736A/zh active Pending
- 2012-11-30 WO PCT/EP2012/004952 patent/WO2013079213A1/en active Application Filing
- 2012-11-30 US US14/361,529 patent/US20140309400A1/en not_active Abandoned
- 2012-11-30 EA EA201491062A patent/EA201491062A1/ru unknown
- 2012-11-30 JP JP2014543802A patent/JP2015500213A/ja active Pending
- 2012-11-30 CA CA2855223A patent/CA2855223A1/en not_active Abandoned
- 2012-11-30 AU AU2012344299A patent/AU2012344299A1/en not_active Abandoned
- 2012-11-30 BR BR112014013041A patent/BR112014013041A2/pt not_active IP Right Cessation
- 2012-11-30 KR KR1020147018105A patent/KR20140099526A/ko not_active Application Discontinuation
-
2014
- 2014-05-19 IL IL232699A patent/IL232699A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL232699A0 (en) | 2014-07-31 |
| WO2013079213A1 (en) | 2013-06-06 |
| KR20140099526A (ko) | 2014-08-12 |
| AU2012344299A1 (en) | 2014-05-29 |
| JP2015500213A (ja) | 2015-01-05 |
| MX2014006399A (es) | 2015-04-10 |
| BR112014013041A2 (pt) | 2019-09-24 |
| EA201491062A1 (ru) | 2014-10-30 |
| CN104023736A (zh) | 2014-09-03 |
| US20140309400A1 (en) | 2014-10-16 |
| CA2855223A1 (en) | 2013-06-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL232699A0 (en) | Use of cell-permeable peptide inhibitors of signal transmitters in the jnk pathway to treat dry eye syndrome | |
| HK1224225A1 (zh) | 信號轉導途徑的細胞滲透肽抑制劑用於治療多種疾病的新用途 | |
| HK1210056A1 (en) | Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of chronic or non-chronic inflammatory eye diseases jnk | |
| HK1221413A1 (zh) | 信號轉導途徑的細胞穿膜肽抑制劑用於治療各種疾病的應用 | |
| HK1200449A1 (en) | Substituted benzylindazoles for use as bub1 kinase inhibitors in the treatment of hyperproliferative diseases bub1 | |
| HUE052433T2 (hu) | N-(3-heteroarilaril)-4-arilarilkarboxamidok és analógjaik mint hedgehog útvonal inhibitorok, továbbá ezek alkalmazása | |
| CO6950481A2 (es) | Inhibidores de proteínas quinasas | |
| IL237918A0 (en) | Azaquinazolines as atypical protein c kinase inhibitors | |
| AP3849A (en) | Use of inhibitors of the activity or function of pi3k | |
| EP2925764A4 (en) | APOPTOSIS PROTEIN INHIBITORS ANTAGONISTS | |
| SG11201401202YA (en) | Antagonists of il17c for the treatment of inflammatory disorders | |
| PL3160489T3 (pl) | Przenikające do komórki inhibitory peptydowe szlaku przekazywania sygnału jnk do leczenia zapalenia pęcherza moczowego | |
| HK1191330A1 (en) | Ethynyl derivatives as positive allosteric modulators of the mglur5 mglur5 | |
| EP3456333B8 (en) | Use of the telomerase inhibitor imetelstat for the treatment of myelodysplastic syndrome | |
| SG11201609335RA (en) | New use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases | |
| EP2663574A4 (en) | RETRO VIRUS REPLICATION INHIBITORS | |
| BR112013023057A2 (pt) | inibidores de peptídeo deformilase | |
| PT2709584T (pt) | Utilização sensorial dos derivados de 6-ciclopentilideno-hexano | |
| GB201216008D0 (en) | Novel use of GSK-3 inhibitors |